GSK to part ways with 'most' Bellus Health employees a year after $2B buy
Many of the employees behind GSK’s late-stage investigational drug for chronic cough will be let go at the end of March.
“After having completed the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
